Hongri Pharmaceutical's latest announcement: net profit in the third quarter fell by 21.98% to 199 million yuan

Hongri Pharmaceutical announced that in the first three quarters of 2021, the company achieved operating income of 5.486 billion yuan, an increase of 16.52% year-on-year; net profit attributable to shareholders of listed companies was 637 million yuan, an increase of 6.34% year-on-year. Among them, in the third quarter of 2021, the company achieved operating income of 2.000 billion yuan, an increase of 3.83% year-on-year; net profit attributable to shareholders of listed companies was 199 million yuan, down 21.98% year-on-year.

According to the 2021 interim report of Hongri Pharmaceutical, the company's main revenue was 3.486 billion yuan, up 25.31% year-on-year; the net profit attributable to the mother was 438 million yuan, up 27.37% year-on-year; the deduction of non-net profit was 425 million yuan, up 46.43% year-on-year; among them, in the second quarter of 2021, the company's single-quarter main revenue was 1.847 billion yuan, up 11.54% year-on-year; the single-quarter net profit attributable to the mother was 245 million yuan, up 4.37% year-on-year. In the single quarter, the non-net profit was 234 million yuan, up 23.45% year-on-year; the debt ratio was 26.78%, the investment income was 1.6486 million yuan, the financial expense was 24.4002 million yuan, and the gross profit margin was 55.48%.

The unit has not had an institutional rating in the last 90 days. In the past three months, the net outflow of financing was 3.718 million, and the balance of financing decreased; the net outflow of margin was 1.9225 million, and the balance of margin decreased. The Securities Star Valuation Analysis Tool shows that Hongri Pharmaceutical (300026) has a good company rating of 3 stars, a good price rating of 2.5 stars, and a comprehensive valuation rating of 3 stars.

The chairman of the company is Yao Xiaoqing. Mr. Yao Xiaoqing: Born in May 1965, Chinese nationality, with Five-year Residency in Australia, Doctoral degree, Senior Engineer, Master Supervisor, founded Tianjin Hongri Pharmaceutical Co., Ltd. in 1996, in 2004, Yao Xiaoqing served as the first person to complete the project "Preparation of Chinese Medicine Hebijing Injection and Its Research on THE PREVENTION and Treatment of SIRS and MODS" and obtained the Tianjin Municipal Science and Technology Achievement Certificate issued by the Tianjin Municipal Science and Technology Commission; In 2007, Yao Xiaoqing was awarded the honorary title of "Tianjin Technological Innovation Leader" by Tianjin Municipal People's Government; In 2011, he won the title of "Eleventh Five-Year Plan" Outstanding Entrepreneur of Tianjin High-tech Zone; In 2013, he was awarded the title of Most Respected Chairman of China's Listed Companies; In 2014, he won the title of Gold Medal Chairman of China Gem And the honorary title of Best Corporate Leader of Golden Bull; In 2015, Yao Xiaoqing was selected as one of the first batch of outstanding entrepreneurs in tianjin's special talent development support program; In 2017, he was selected as the "Innovative Talent Promotion Plan of the Ministry of Science and Technology" and the third batch of leading talents of the national "Ten Thousand Talents Plan"; In 2018, he won the title of chairman with the most strategic vision in the "Golden Round Table Award" of the 13th Board of Directors of Listed Companies in China; In 2020, he won the first prize of Tianjin Science and Technology Progress Award - the first person to complete the "Clinical and Mechanism Research on the Efficacy of Hebijing Injection in the Treatment of Pneumonia Infected by Novel Coronavirus Infection", the National Poverty Alleviation Dedication Award, and the title of Advanced Individual in Poverty Alleviation Collaboration and Support Cooperation in Tianjin. He was a physician at the Third Hospital of Tianjin. He is currently the chairman of the company, the vice president of the China Association of Chinese Medicines, the president of the Tianjin Pharmaceutical International Exchange Association, the member of the Tianjin Municipal Committee of the Revolutionary Committee of the Chinese Kuomintang, and the president of the Tianjin Enterprise Friendship Association of the Revolutionary Committee of the Chinese Kuomintang.

This article is compiled by the Securities Star Data Center based on publicly available data and does not constitute investment opinions or suggestions, if there are any problems in the text, please contact us.